This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2016 Mar 8;315(10):984-6.

doi: 10.1001/jama.2016.1461.

Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A Study Interrupted

Joshua M Sharfstein¹, Bruce M Psaty²

Affiliations

Affiliations

¹ Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
² Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle3Group Health Research Institute, Group Health Cooperative, Seattle, Washington.

PMID: 26954405
DOI: 10.1001/jama.2016.1461

Editorial

Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A Study Interrupted

Joshua M Sharfstein et al. JAMA. 2016.

. 2016 Mar 8;315(10):984-6.

doi: 10.1001/jama.2016.1461.

Authors

Joshua M Sharfstein¹, Bruce M Psaty²

Affiliations

¹ Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
² Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle3Group Health Research Institute, Group Health Cooperative, Seattle, Washington.

PMID: 26954405
DOI: 10.1001/jama.2016.1461

No abstract available

PubMed Disclaimer

Comment on

Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, Perez A, Smith SR. Nissen SE, et al. JAMA. 2016 Mar 8;315(10):990-1004. doi: 10.1001/jama.2016.1558. JAMA. 2016. PMID: 26954408 Clinical Trial.

Similar articles

Time-to-Event Analysis.
Tolles J, Lewis RJ. Tolles J, et al. JAMA. 2016 Mar 8;315(10):1046-7. doi: 10.1001/jama.2016.1825. JAMA. 2016. PMID: 26954413 No abstract available.
Company is blamed for early halt of trial into obesity treatment.
Wise J. Wise J. BMJ. 2016 Mar 8;352:i1363. doi: 10.1136/bmj.i1363. BMJ. 2016. PMID: 26962129 No abstract available.
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, Perez A, Smith SR. Nissen SE, et al. JAMA. 2016 Mar 8;315(10):990-1004. doi: 10.1001/jama.2016.1558. JAMA. 2016. PMID: 26954408 Clinical Trial.
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
Verpeut JL, Bello NT. Verpeut JL, et al. Expert Opin Drug Saf. 2014 Jun;13(6):831-41. doi: 10.1517/14740338.2014.909405. Epub 2014 Apr 28. Expert Opin Drug Saf. 2014. PMID: 24766397 Review.
Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
Ali KF, Shukla AP, Aronne LJ. Ali KF, et al. Expert Rev Clin Pharmacol. 2016;9(1):27-34. doi: 10.1586/17512433.2016.1100072. Epub 2015 Oct 29. Expert Rev Clin Pharmacol. 2016. PMID: 26512740 Review.

See all similar articles

Cited by

Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis.
Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland IJ, Berry JD, Camilleri M, Singh S. Khera R, et al. Gastroenterology. 2018 Apr;154(5):1309-1319.e7. doi: 10.1053/j.gastro.2017.12.024. Epub 2018 Jan 3. Gastroenterology. 2018. PMID: 29305933 Free PMC article.
Data Monitoring Committees: Current issues.
Fleming TR, Ellenberg SS, DeMets DL. Fleming TR, et al. Clin Trials. 2018 Aug;15(4):321-328. doi: 10.1177/1740774518764855. Epub 2018 Apr 9. Clin Trials. 2018. PMID: 29629815 Free PMC article.
Data Safety and Monitoring Boards Should Be Required for Both Early- and Late-Phase Clinical Trials.
Van Norman GA. Van Norman GA. JACC Basic Transl Sci. 2021 Nov 22;6(11):887-896. doi: 10.1016/j.jacbts.2021.09.005. eCollection 2021 Nov. JACC Basic Transl Sci. 2021. PMID: 34869954 Free PMC article.
Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview.
Telci Caklili O, Cesur M, Mikhailidis DP, Rizzo M. Telci Caklili O, et al. Diabetes Metab Syndr Obes. 2023 Jun 14;16:1767-1774. doi: 10.2147/DMSO.S392684. eCollection 2023. Diabetes Metab Syndr Obes. 2023. PMID: 37337548 Free PMC article. Review.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information